Daiichi Sankyo- Lilly Announce New Prasugrel
Head-to-Head Phase III Study Against Clopidogrel
<strong>Duke Clinical Research Institute to lead multinationalstudy with investigational compound; will include 10-000 medicallymanaged patients with acute coronary syndrome</strong>